OBJECTIVE: To determine the timeliness of consultation and initiation of disease-modifying antirheumatic drugs (DMARD) in patients with rheumatoid arthritis (RA) referred to rheumatologists. METHODS: The first part of the study was a review of the charts of 151 patients with RA followed by 3 rheumatologists. The outcome measure was the interval between symptom onset and consultation with a rheumatologist. The second part of the study involved a chart review of 4 family physician practices in a small urban center in order to determine the accuracy of diagnostic coding (International Classification of Diseases; ICD-9) of RA, as well as the proportion of patients with RA seen by a rheumatologist. Finally, a survey was sent to primary care physicians at a group of walk-in clinics to determine what percentage of their patients with RA were referred to a rheumatologist and, concerning referral patterns, how likely it is they would refer a confirmed or suspected RA patient to a rheumatologist. RESULTS: Patients with RA referred to rheumatologists in this sample were seen by a rheumatologist at a mean of 9.8 months (median 5 mo, range 0-129 mo) after symptom onset, and mean 1.2 months (median 4.0 mo, range 0-8 mo) after being referred by their primary care physician. All referred patients with confirmed RA were started on DMARD within 1 week of initial consultation. Primary care physicians would refer suspected RA patients 99.5% of the time (median 100, range 90-100%), and 87.6% (median 90, range 50-100%) of patients with confirmed RA would have seen a rheumatologist at least once. A chart review showed that, in a select group of family physicians, 70.9% (22/31) of patients coded as RA per the ICD-9 did indeed have RA and all had seen a rheumatologist for their condition. CONCLUSION: In Northern Alberta, patients with RA are seen and started on DMARD therapy in a timely fashion. Most of the delay is at the primary care level, suggesting a need for improved education of patients and primary care physicians rather than a formal triage system.
OBJECTIVE: To determine the timeliness of consultation and initiation of disease-modifying antirheumatic drugs (DMARD) in patients with rheumatoid arthritis (RA) referred to rheumatologists. METHODS: The first part of the study was a review of the charts of 151 patients with RA followed by 3 rheumatologists. The outcome measure was the interval between symptom onset and consultation with a rheumatologist. The second part of the study involved a chart review of 4 family physician practices in a small urban center in order to determine the accuracy of diagnostic coding (International Classification of Diseases; ICD-9) of RA, as well as the proportion of patients with RA seen by a rheumatologist. Finally, a survey was sent to primary care physicians at a group of walk-in clinics to determine what percentage of their patients with RA were referred to a rheumatologist and, concerning referral patterns, how likely it is they would refer a confirmed or suspected RApatient to a rheumatologist. RESULTS:Patients with RA referred to rheumatologists in this sample were seen by a rheumatologist at a mean of 9.8 months (median 5 mo, range 0-129 mo) after symptom onset, and mean 1.2 months (median 4.0 mo, range 0-8 mo) after being referred by their primary care physician. All referred patients with confirmed RA were started on DMARD within 1 week of initial consultation. Primary care physicians would refer suspected RApatients 99.5% of the time (median 100, range 90-100%), and 87.6% (median 90, range 50-100%) of patients with confirmed RA would have seen a rheumatologist at least once. A chart review showed that, in a select group of family physicians, 70.9% (22/31) of patients coded as RA per the ICD-9 did indeed have RA and all had seen a rheumatologist for their condition. CONCLUSION: In Northern Alberta, patients with RA are seen and started on DMARD therapy in a timely fashion. Most of the delay is at the primary care level, suggesting a need for improved education of patients and primary care physicians rather than a formal triage system.
Authors: Jessica Widdifield; Sasha Bernatsky; J Carter Thorne; Claire Bombardier; R Liisa Jaakkimainen; Laura Wing; J Michael Paterson; Noah Ivers; Debra Butt; Anne Lyddiatt; Catherine Hofstetter; Vandana Ahluwalia; Karen Tu Journal: CMAJ Open Date: 2016-05-11
Authors: Cheryl Barnabe; Juan Xiong; Janet E Pope; Gilles Boire; Carol Hitchon; Boulos Haraoui; J Carter Thorne; Diane Tin; Edward C Keystone; Vivian P Bykerk Journal: Rheumatol Int Date: 2013-08-30 Impact factor: 2.631
Authors: Alaa S Barhamain; Rami F Magliah; Mohammad H Shaheen; Shurooq F Munassar; Ayman M Falemban; Mohammed M Alshareef; Hani M Almoallim Journal: Open Access Rheumatol Date: 2017-07-28
Authors: Rebecca Jayne Stack; Peter Nightingale; Clare Jinks; Karen Shaw; Sandy Herron-Marx; Rob Horne; Chris Deighton; Patrick Kiely; Christian Mallen; Karim Raza Journal: BMJ Open Date: 2019-03-04 Impact factor: 2.692
Authors: Maame-Boatemaa Amissah-Arthur; Anna Gyaban-Mensah; Vincent Boima; Ernest Yorke; Dzifa Dey; Vincent Ganu; Charles Mate-Kole Journal: PLoS One Date: 2022-09-12 Impact factor: 3.752
Authors: Diederik De Cock; Kristien Van der Elst; Veerle Stouten; Donna Peerboom; Johan Joly; Rene Westhovens; Patrick Verschueren Journal: Rheumatol Adv Pract Date: 2019-08-30